This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Angeliq Regulatory Post Marketing Surveillance (Angeliq rPMS)

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: February 5, 2010
Last updated: November 18, 2013
Last verified: November 2013
Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA). This is non-interventional , prospective, multi-center study.Target number of patients is 4500.

Condition Intervention
Postmenopausal Period Osteoporosis, Postmenopausal Drug: E2/DRSP (Angeliq, BAY86-4891)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Angeliq Regulatory Post Marketing Surveillance

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Adverse event collection [ Time Frame: At each visit of patient during observational period (6 months) ]

Secondary Outcome Measures:
  • Improvement of menopausal symptoms [ Time Frame: After 6 months or at discontinuation of Angeliq (At earlier point) ]

Enrollment: 4078
Study Start Date: June 2007
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: E2/DRSP (Angeliq, BAY86-4891)
Take one tablet daily, continuously


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Korean women who take Angeliq for postmenopausal symptoms or/and prevention of osteoporosis

Inclusion Criteria:

  • Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women more than 1 year postmenopause
  • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis

Exclusion Criteria:

  • Undiagnosed genital bleeding
  • Known, past or suspected cancer of the breast
  • Known or suspected estrogen-dependent malignant tumors (e.g. endometrial cancer)
  • Untreated endometrial hyperplasia
  • Previous idiopathic or current venous thromboembolism (e.g. deep venous thrombosis, pulmonary embolism)
  • Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction)
  • Acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal
  • Porphyria
  • Severe renal insufficiency or acute renal failure
  • Known hypersensitivity to the active substances or to any of the excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01064453

Korea, Republic of
Many Locations, Korea, Republic of
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT01064453     History of Changes
Other Study ID Numbers: 14841
AQ0710KR ( Other Identifier: company internal )
Study First Received: February 5, 2010
Last Updated: November 18, 2013

Keywords provided by Bayer:
Menopausal symptoms
Prevention of osteoporosis in menopausal women
Estrogen deficiency symptoms
Hormone replacement therapy

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Drospirenone and ethinyl estradiol combination
Reproductive Control Agents
Physiological Effects of Drugs processed this record on September 21, 2017